The ‘OneWorld’ health model and the prospects for future development of therapeutics for infectious disease of the developing world

Type :

Term papers

Pages :

15 pages

Format :

.doc

Published date :

03/05/2009

Category :

Science & technology

Sub category :

Medical studies

Oboulo.com selection criteria

$ 19.95 Add to cart

Summary :

Introduction.
Research and development for safe efficacious antimicrobials.
Recognition of market failure and the genesis of One World Health.
1. The visionary behind One World Health.
2. Four unique features of this model.
3. Two major roadblocks.
A report card at six years.
1. Studies on paromomycin.
2. Clinical trials, market approval and establishing a manufacturing partner.
Post-approval challenges and opportunities.
1. The challenge of distribution in rural and developing communities: How does Coke do it?
2. The challenge of local manufacture of pharmaceuticals: Lessons from Brazil's HIV/AIDS efforts.
One World Health's Innovation and the Implications for pharmaceutical pipelines and access to information.
Additional opportunities for innovation by One World Health.
1. Scientific networks.
2. Financial support.
Summary of recommendations.
Implications for health disparities.

Abstract

Despite the vast improvements in health care and prevention of infectious diseases in the developed world, six out of ten deaths in the developing world can still be directly attributed to infectious disease. Diarrheal diseases, lower respiratory infections, malaria, measles, TB, and HIV/AIDS kill literally millions of children each year. Morbidity and mortality due to infectious disease is a key driving force behind the underdevelopment of economies, particularly in the global South. There are compelling political, economic, social, and moral interests at stake surrounding the decision of private industry and public institutions to invest in the development of treatments for infectious diseases in the developing world. However, the medical research and development infrastructure as it stands fails to address the substantial medical challenges that subsequently place vulnerable communities at a disadvantage. Research and development for safe, efficacious antimicrobials for developing world diseases lacks for several reasons. Pharmaceutical companies considering their financial goals suggest they are unable to develop drugs for developing world diseases because individuals in the developing world will not be able to purchase the drug such that the company makes a significant profit. Without a guaranteed large market, the current model for pharmaceutical research and development fails.